Seilern Investment Management Ltd Trims Holdings in IDEXX Laboratories, Inc. $IDXX

Seilern Investment Management Ltd trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,790 shares of the company’s stock after selling 40,486 shares during the quarter. IDEXX Laboratories comprises about 5.3% of Seilern Investment Management Ltd’s investment portfolio, making the stock its 13th biggest holding. Seilern Investment Management Ltd’s holdings in IDEXX Laboratories were worth $68,187,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories in the third quarter worth about $26,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $30,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $31,000. Armstrong Advisory Group Inc. boosted its position in shares of IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares in the last quarter. Finally, Salomon & Ludwin LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $35,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of analyst reports. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. UBS Group reduced their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, Barclays reduced their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Stock Up 0.2%

IDXX stock opened at $578.51 on Tuesday. The stock has a market capitalization of $46.00 billion, a P/E ratio of 44.26, a P/E/G ratio of 3.50 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The business has a fifty day moving average price of $642.81 and a 200-day moving average price of $664.28.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the business earned $2.53 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.